Member Info for Hurst10

FYI:

GTC 2024: Nvidia Highlights AI 'Revolution' in Drug Discovery, Genomics

Gives Novo even more cash to acquire further!

AVCT Therapeutics would fit nicely.

:

Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by Astra Zeneca.

Deal value up to US$1.05 billion

Novo Holdings co-led Series A financing in Amolyt, supported additional financings and is Amolyt's largest investor

Acquisition validates Novo Holdings' strategy to identify and invest long term in high quality European biotech companies

On the exchange, the term "shortly "can/ could be in the next couple of weeks.

Never mind, let us just focus on the "new"shareholder list, a well known European life science fund, could be anything from Allianz to Novartis. How convenient in front of the AACR presentation .

Https://accsindia.org/adcom2022/

BMY and JNJ

Meanwhile AVA6000 about to present shortly!

Ahead of ADCOM:

The U.S. Food and Drug Administration's staff reviewers on Wednesday raised safety concerns over the use of Johnson & Johnson's and Bristol-Myers Squibb's cancer therapies as earlier treatments for blood cancer patients.

Staff reviewers said that the pattern of early deaths observed in patients treated with both the therapies in their respective trials raised uncertainty about their overall survival benefit.

The therapies - J&J's Carvykti and Bristol Myers' Abecma - are approved by the FDA to treat patients with multiple myeloma who have received at least four prior lines of treatment.

Reading some of the replies on the boards, it always reminds of what an old senior partner once said to me :

" Better to remain silent and be thought a fool, than to speak and to remove all doubt".

Remind me next week when AVCT is trading north of 135p

But you are selling it seems, good luck.

Remind me next week when AVCT is trading north of 135p

But you are selling it seems, good luck

Back to business, in today's trading, with earlier NY hours- we have had est 300/ purchased over the last couple of hours and the buying will now accelerate and once again an attempt to break though 60-5p level and then fast track rest of the week, with more M&A State side as well. Lively couple of weeks pre AACR coming up.

Always good to load up during news embargo !

Sorry if repeat, NY moved forward an hour!

Another size order and we will be 61-3 shortly and over 4 mill traded

A familiar gentlemen now at the helm of Affyxell, wants to move things forward and have the compass firmly pointed on Wall street,one wonder what valuation Avacta really have for their no cost holding or are the Chinese going to buy their holding/acquire Affyxell before all that?

Meanwhile the size buyer is back in town and he wants stock!

Maleria link is fake story, site well known for it!

Meanwhile back to the market!

I do indeed know of their part ownership, as we should all do !

However it does not stop them researching Affimer.

We will still have an old fashioned Friday with size buyers moving it above 70, at Friday close .

More news before conference I suspect .

Size buyers are indeed back early!

60 p being lifted in size pre NY .

Did we look at Affimers and anti obesity?

From JBC :

October 2023

Affimer” synthetic protein scaffolds block oxidized LDL binding to the LOX-1 scavenger receptor and inhibit ERK1/2 activation

The valuation of the AVA pipeline could post AACR be worth 20x current price.

pre IPO !

This is the bullish language we will hear at AACR:

"Critically, this financing provides Avacta with 24 months of cash runway to focus on advancing AVA6000 through the clinic, as well as progressing other assets earlier in the development cycle to hit key commercial milestones."

Bicycle Therapeutics up another 7% pre market .

Recently we had Braker brothers well known hedge fund in the biotech area, increasing their stake significantly, BCYC have strong read across to Avacta.